Influence of Environmental and Community Factors on Psoriasis: A Comprehensive Review of Pollution, Urban Design, and Socioeconomic Risk Factors - Top-Institutions - MDSpire

Influence of Environmental and Community Factors on Psoriasis: A Comprehensive Review of Pollution, Urban Design, and Socioeconomic Risk Factors

  • By

  • Parsa Mokhtar

  • Josep Riera Monroig

  • Allison Kranyak

  • Wilson Liao

  • April 2, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health

    Boston, MA

    Key Differentiators

    • Dermatology
    • Environmental Health
    • Epidemiology

  • #2

    National Institute of Environmental Health Sciences (NIEHS)
    National Institute of Environmental Health Sciences (NIEHS)

    Research Triangle Park, NC

    Key Differentiators

    • Environmental Health
    • Immunology
    • Dermatology

  • #3

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Public Health

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Environmental Medicine
    • Epidemiology

  • #5

    University of Michigan School of Public Health
    University of Michigan School of Public Health

    Ann Arbor, MI

    Key Differentiators

    • Environmental Health Sciences
    • Dermatology
    • Epidemiology

Original Source(s)

Influence of Environmental and Community Factors on Psoriasis: A Comprehensive Review of Pollution, Urban Design, and Socioeconomic Risk Factors

  • by Parsa Mokhtar, Josep Riera Monroig, Allison Kranyak, Wilson Liao

  • April 2, 2026

Related Content

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study